Objective-Myogenic tone (MT) of resistance arteries ensures autoregulation of blood flow in organs and relies on the intrinsic property of smooth muscle to contract in response to stretch. Nucleotides released by mechanical strain on cells are responsible for pleiotropic vascular effects, including vasoconstriction. Here, we evaluated the contribution of extracellular nucleotides to MT. Approach and Results-We measured MT and the associated pathway in mouse mesenteric resistance arteries using arteriography for small arteries and molecular biology. Of the P2 receptors in mouse mesenteric resistance arteries, mRNA expression of P2X 1 and P2Y 6 was dominant. P2Y 6 fully sustained UDP/UTP-induced contraction (abrogated in P2ry6 −/− arteries). Preventing nucleotide hydrolysis with the ectonucleotidase inhibitor ARL67156 enhanced pressureinduced MT by 20%, whereas P2Y 6 receptor blockade blunted MT in mouse mesenteric resistance arteries and human subcutaneous arteries. Despite normal hemodynamic parameters, P2ry6 −/− mice were protected against MT elevation in myocardial infarction-induced heart failure. Although both P2Y 6 and P2Y 2 receptors contributed to calcium mobilization, 
M yogenic tone (MT) underlies the ability of small arteries to contract in response to increased internal pressure. 1 This mechanism ensures constant organ perfusion, reducing flow as pressure increases, and increasing flow when pressure drops to prevent tissue damage and edema from elevated pressure in capillaries. Abnormal MT has been reported in vascular dysfunctions related to vasospasm, 2 chronic heart failure (CHF), 3 cardiomyopathies, 4 and hypertension. 5 Resetting of MT has been proposed as a valuable strategy to protect sensitive vascular territories. 6 MT is an intrinsic property of smooth muscle cells (SMCs), occurring independently of neurohumoral or endothelial input. Pressure sensing in SMCs implicates an integrated mechanotransduction, allowing conversion of wall stress into cell contraction. 6 Pressure induces conformational changes in extracellular matrix protein-binding adhesion sites in the cell membrane, mainly integrins. 7 The mechanical stimulus is transmitted to the submembrane space through several mechanosensitive structures. The opening of stretch-operated channels results in cationic (predominantly Na + ) current, sustaining membrane depolarization. 6 The resulting secondary calcium entry through voltage-gated Ca 2+ channels is essential for electromechanical coupling of MT. The molecular identity of cation channels leading to stretch-induced depolarization is unknown, but transient receptor potential channels may have a large role. 8 Recent data suggest that G-protein-coupled receptors (GPCRs) contribute to MT, 9 at the fore of which is angiotensin II (AngII) type 1 receptor. 10 This receptor, proposed to be a mechanosensor activated in an agonist-independent manner, 11 directly couples to transient receptor potential through the G q -protein pathway. This scheme sequentially associates GPCRs and transient receptor potential channels, mediating the effects of pharmacological inhibitors of both entities on MT. 10 However, several points remain to be clarified: the redundancy of the process with other GPCRs, the means of receptor activation, and the intracellular signaling pathways implicated.
In the vasculature, extracellular nucleotides participate in local control of blood flow through activation of P2 receptors. Two types of P2 receptors, ionotropic P2X [1] [2] [3] [4] [5] [6] [7] and G-protein-coupled P2Y, 1,2,4,6,11-14 bind both purine and pyrimidine. 12 Activation of endothelial P2 receptors induces local vasorelaxation, whereas direct activation of vascular SMC receptors promotes vasoconstriction via P2X 1 or pyrimidine-sensitive P2Y receptors. 12 Besides the well-known granular ATP secretion by platelets and nerve terminals, nonvesicular release of nucleotides occurs in virtually all cells. Such release occurs on agonist, chemical, or mechanical stimulation, appearing to involve a variety of anionic pore-forming membrane proteins, such as pannexins, connexins, P2X 7 receptor, or ATP-binding cassette transporters. 13 Here, we assessed the contribution of extracellular nucleotides and specific P2 receptors to the development of pressureinduced MT.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Expression of P2 Receptors in Mesenteric Resistance Arteries
We evaluated the expression pattern of P2 nucleotide receptors in mesenteric resistance arteries (MRAs) by quantitative reverse transcription polymerase chain reaction. P2Y 6 was the most expressed P2Y receptor, followed by P2Y 1 and P2Y 2 and to a lesser extent P2Y 12, 13 and P2Y 14 (no detectable P2Y 4 ). Among P2X receptors, P2X 1 was most expressed in MRAs, which is in agreement with previous work, 14 followed by P2X 7 and P2X 4 and to a lesser extent P2X 5 ; P2X 6, P2X 2 , and P2X 3 were barely detected ( Figure 1A ).
Impaired Contraction in P2ry6 −/− MRAs
The contractile response to the uracil nucleotide UDP, its nonhydrolyzable analog UDPβS, and UTP were abrogated in P2ry6 −/− MRAs ( Figure 1B through 1D ). Concentrationresponse curves to phenylephrine, endothelin-1, AngII, and the stable thromboxane A2/PGH2 receptor agonist U46619 were unaffected by the absence of P2Y 6 receptor ( Figure 1E and 1H). Moreover, endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) relaxations were comparable in both mice strains ( Figure 1I and 1J). As previously described in MRAs, ATP induced transient contraction through activation of the P2X 1 ligand-gated channel.
14 This response was prevented by pharmacological blockade (NF449) or desensitization (α,β-MeATP) of P2X 1 receptor. P2X 1 
P2ry6 Deletion Protects Against Pathological Increase in MT
To evaluate the potential impact of P2Y 6 15 consistent with a P2Y 6 receptor effect on blood pressure regulation in pathological conditions.
CHF is known to induce increased peripheral vascular resistance, partly through enhanced MT. 3 In P2ry6
animals, CHF (induced by coronary artery ligation; Figure VII in the online-only Data Supplement) was associated with a significant increase in MT ( range, 50-100 mm Hg), an increase not observed in P2ry6 −/− animals ( Figure 3A ). Concentrationresponse curves to phenylephrine were comparable in both genotypes and not modified by CHF ( Figure 3B ).
P2Y 6 Receptor-Induced Signaling Pathways
Besides intracellular calcium mobilization, several signaling pathways participate in MT, including RhoA/Rho kinase, P38 and P42-P44 (extracellular signal-regulated kinases 1 and 2) mitogen-activated protein kinase, and PI3-kinase-γ. [16] [17] [18] We evaluated the ability of P2Y 6 receptor to trigger these pathways. UDP, UTP, and ATP induced intracellular calcium increase in wild-type arterial SMCs in a concentration-dependent manner. In P2ry6 −/− cells, calcium mobilization was abrogated in response to UDP but only slightly diminished in response to UTP and normal in response to ATP, suggesting that P2Y 2 receptors (UTP/ATP) are functional and can mobilize calcium in the absence of P2Y 6 ( Figure 4A ). As the expression pattern of receptors in arterial SMCs may vary in culture, we compared nucleotide-induced calcium mobilization in freshly dissociated and early passage (P2) SMCs isolated from MRAs, which gave similar results (Figure VIII in the online-only Data Supplement).
The active form (GTP bound) of the small G-protein RhoA was quantified by pull-down after nucleotide stimulation. UDP, UTP, or UDPβS increased GTP binding to Rho in aortic rings. This response was abrogated in P2ry6 −/− arteries, whereas response to the thromboxane-A2 analog U46619 was preserved ( Figure 4B ).
In P2ry6 +/+ SMCs, P2Y 6 stimulation (UDP) induced concentration-dependent phosphorylation of myosin light chain associated with a trend toward increased myosin light chain phosphatase (ser-696 and ser-853) and mitogen-activated protein kinase extracellular signal-regulated kinase (P42-P44), P38, and c-Jun N-terminal kinase. These phosphorylations were abrogated in P2ry6 −/− cells ( Figure 4C ; Figure X in the online-only Data Supplement).
Hemichannel-Dependent Nucleotide Release
Endogenous extracellular nucleotide release can occur through the opening of membrane pore-forming proteins belonging mainly to the Panx and Cx families. We evaluated the expression and potential contribution of these proteins to MT. Quantitative reverse transcription polymerase chain reaction performed on RNA isolated from mouse MRAs revealed the presence of Cx, commonly described in the vasculature (Cx37>Cx45≈Cx40>Cx43) and Panx1, but not in . Pharmacological blockers of connexin channels (18α-glycyrrhetinic acid, flufenamic acid, and carbenoxolone) reduced MT significantly, whereas the more selective Panx1 blockers (probenecid, mefloquine, or 10 Panxblocking peptide) had no effect ( Figure 5B), consistent with normal MT in Panx1 −/− mice despite reduced phenylephrine-induced contraction ( Figure 5C and 5D), as previously described. 19 Although Cx37 deletion did not diminish MT ( Figure 5E ), the response was significantly reduced in Cx43 +/− and P2rx7 −/− animals ( Figure 5F and 5G). MT was inhibited by KN62, a P2X 7 antagonist ( Figure 5B 
Discussion
In addition to the well-described neurogenic release of ATP with noradrenaline that contributes to sympathetic tone, uracil nucleotides are vasoconstrictor mediators in many vascular territories through activation of P2Y 2,4,6 receptors. Despite many in vitro investigations of purinergic signaling in the cardiovascular system, the pathophysiological implications remain misunderstood. 12 In this study, we show that P2Y 6 UDP receptor, the most expressed P2Y receptor in mouse resistance arteries, is required for maintaining proper arterial tone. This receptor fully supports in vitro arterial contraction in response to UDP and UTP and substantially contributes to MT through an autocrine/paracrine activation loop.
Our results indicate that MT was also sensitive to pharmacological inhibition of P2Y 6 by reactive blue-2 in human subcutaneous arteries, suggesting that some human small arteries may develop MT, at least in part, through the mechanism described here.
This observation adds to the emerging concept that GPCRs participate in MT. 9 A comprehensive scheme of P2Y 6 receptor activation and its contribution to MT is represented in Figure 6 .
As a G q -coupled receptor, P2Y 6 activates phospholipase-Cβ and increases intracellular calcium through inositol triphosphate-sensitive stores 20 and protein kinase C activity through diacyl glycerol formation. We showed that calcium increase was abrogated in P2ry6 −/− arterial SMCs (freshly dissociated and cultured cells) stimulated by UDP but only marginally affected after UTP/ATP stimulation. These results suggest efficient coupling of P2Y 2 (UTP/ATP) receptor to calcium mobilization, whereas P2Y 6 modestly contributes to this response. Unlike P2ry6 −/− animals, P2ry2 −/− mice did not display altered MT ( Figure IX in the online-only Data Supplement) highlighting a nonredundant role of P2Y 6 receptor in MT where intracellular calcium increase is minimally involved.
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P2Y 6 receptor activation induced phosphorylation of mitogen-activated protein kinase, including P38, P42-44, and c-Jun N-terminal kinase. P38 is involved in MT 17 and contributes to blood pressure rise after CHF, a condition characterized by elevated peripheral resistance with a major myogenic component. 22 In contrast, P42/44 extracellular signal-regulated A C B kinase 1/2 is activated by cell stretch with no causal relationship with MT. 23 c-Jun N-terminal kinase is a stress-activated protein kinase sensitive to UV irradiation, heat, and osmotic shock.
24 P2Y 6 receptor has also been implicated in the cellular response to these stresses 25, 26 ; thus, c-Jun N-terminal kinase activation by P2Y 6 receptor may represent a cellular stress response, such as SMC response to stretch.
Gα 12/13 proteins activate the small G-protein RhoA and constitute, with Rho-kinase, a calcium-sensitizing pathway, promoting myosin light chain phosphorylation through inhibition of phosphatase. GTP binding to RhoA in response to UDP/UTP was suppressed in P2ry6 −/− mice. We have already shown that the RhoA-Rho kinase pathway contributes to MT. 27 Thus, activation of the G 12/13 Rho-kinase pathway may explain a large part of the exclusive contribution of P2Y 6 to MT.
Although the real trigger of MT remains to be established, in physiology, maintenance of the response (myogenic contraction) is consistent with protection of downstream capillaries pressure overload: MT lasts when pressure remains elevated. How the same mechanism participates in both triggering and sustaining the response to pressure is an old debate. Although the molecular determinants remain to be identified, membrane tensegrity seems to be central to mechanosensation. Tensegrity stabilizes cell shape by providing continuous tension that depends on cytoskeletal integration of mechanical forces through interactions with the extracellular matrix and adhesion molecules; it results in tangential forces that develop at the membrane. 28 The resulting signal transduction converges on actin-myosin interaction and cellular contraction.
1 Our hypothesis ( Figure 6 ) places the P2Y 6 activation loop below mechanical perception, which should therefore be maintained as the tangential forces are applied to the membrane. Moreover, P2Y 6 displays slow desensitization 29 ; this, combined with the fact that the receptor activates the calcium-sensitizing pathway, suggests that a single activation after UDP release may last over time.
Mechanical strains are well known to trigger nucleotide release. 30 Here, we propose that vascular cell stretch caused by a rise in intraluminal pressure induces the release of nucleotides that stimulate P2Y 6 and promote SMC contraction. This hypothesis may diverge from recent data showing that AngII type 1 receptor can be activated by stretch in an agonist-independent manner. 10 Key observations argue in favor of autocrine/paracrine nucleotide release rather than direct activation by stretch. First, diminishing extracellular nucleotide hydrolysis with an ectonucleoside triphosphate diphosphohydrolase-1 (or CD39) inhibitor, the dominant arterial ectonucleotidase, enhanced MT, in agreement with our previous work showing that MT is exacerbated in Entpd1 −/− mouse arteries. 31 Second, pharmacological interference with nucleotide-releasing molecules reduced MT similarly to P2Y 6 receptor blockade or deletion, in accordance with the effect of a pharmacological connexin channel blockade on MT. 32, 33 Candidate protein-releasing nucleotides should be permeable to anions and mechanosensitive. Such properties are held by connexins and pannexins, suggesting that they open in response to mechanical forces. 34 Unlike connexins, pannexins do not form cell-to-cell channels but only single-membrane channels. 35 Notably, Panx1 is involved in ATP release in response to adrenergic receptor stimulation. 19 Nevertheless, MT was not diminished in Panx1 −/− arteries and not affected by Panx1 inhibitors, ruling out its contribution to MT.
Similarly, Cx37 can function as a hemichannel. 36 A reverse relationship exists between Cx37 expression level and arterial diameter 37 ; we found that Cx37 displayed the largest expression level in MRAs. However, MT was not reduced in Cx37 −/− arteries-it was potentiated-ruling out its contribution in mechanosensitive-nucleotide release. However, MT was reduced in Cx43 +/− mice arteries. Notably, the MRAs of Cx43 −/− mice could not be studied because of the lethality of these mice at birth. 38 The opening of Cx43 hemichannels may involve other partners, among them P2X 7 receptors. 39 MT was similarly reduced in MRAs from P2rx7 −/− mice, and a pharmacological blockade of P2X 7 strongly reduced it. P2X 7 receptors can form large pores, 40 and heterologous expression allows cells to release ATP in response to hypotonic swelling. 41 The receptor has a long C-terminal cytoplasmic tail that binds to integrins or cytoskeletal elements (α-actin, α-actinin, supervillin) 42 putatively implicated in mechanosensation. These data suggest that the P2X 7 opening is sensitive to membrane stretch. P2Y 6 and P2X 7 receptors are characterized by slow desensitization 29, 40 ; thus, their contribution to MT may occur in a nontransient manner. Their sensitivity to mechanical deformation and their ability to release nucleotides suggest that P2X 7 and Cx43 are involved in MT through cellular nucleotide release. A direct molecular association of the 2 proteins was described in macrophages 39 and could potentially occur in arterial SMCs. Moreover, CarioToumaniantz et al 43 reported P2X 7 -dependent vascular contraction in human saphenous veins: P2X 7 activation formed membrane pores permeable to large molecules, promoting myocyte contraction followed by cell lysis when stimulation was maintained. For unknown reasons, we did not observe P2X 7 -dependent contraction in our setting ( Figure XI in the online-only Data Supplement). P2X 7 receptor was initially described as an apoptosis promotor; since then, it has been implicated in many complex cellular processes, including potassium efflux and NLRP3/inflammasome activation, 44 transglutaminase-2 secretion, 45 permeability to chloride, 46 and amyloid precursor protein secretion. 47 Intriguingly, these mechanisms could be dissociated from cellular depolarization. Hence, P2X 7 function remains enigmatic; characterization of its activation mechanism in the context of MT represents a challenging future investigation.
Thus, besides the existing therapeutic tools targeting arterial tone, drugs targeting P2Y 6 or associated pressuresensitive pores could more selectively target MT. This is especially important as MT so far cannot be selectively targeted, although resetting it may represent a new therapeutic option. 6 The emergence of GPCRs, such as sphingosine-1-phosphate, prostanoids, cysteinyl leukotriene, or AngII receptors 9, 48 as MT modulators, may offer such opportunity.
As demonstrated in this study, purinergic signaling, often presented as a danger signal, 49 is involved in acute arterial response to pressure. This may be important in various vascular disorders at the foreground CHF, a condition associated with increased peripheral vascular resistance and exacerbated MT. 3 We found that the absence of P2Y 6 receptor protects against the increase in MT in heart failure after myocardial infarction. In the long-term, chronic overstimulation of P2Y 6 may play a role not only in defective tissue perfusion (ie, brain) 50 but also in deleterious arterial remodeling associated with ischemic/inflammatory arteriopathies. 51 Interestingly, recent investigations reported that P2Y 6 is also involved in long-term arterial remodeling associated with aging and hypertension through specific synergistic interaction with AngII receptors. 15 Altogether these data indicate that P2Y 6 receptor might constitute a valuable target in vascular diseases associated with impaired tissue perfusion.
We describe a new mechanism contributing to MT development that shares a common pathway with cellular stress (inflammation and swelling). GPCRs to date represent the target for nearly half of currently available drugs, but drugs exploit only a limited number of receptors 52 ; thus, unraveling the expression and contribution of arterial GPCRs is mandatory. Specific targeting of P2Y 6 may be advantageous in a pathological context in which MT is impaired (heart failure, diabetes mellitus, and hypoxia).
